X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ELDER PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ELDER PHARMA IPCA LABS/
ELDER PHARMA
 
P/E (TTM) x 25.3 -0.2 - View Chart
P/BV x 4.3 0.1 4,249.0% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ELDER PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ELDER PHARMA
Jun-14
IPCA LABS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs695380 183.0%   
Low Rs400188 212.8%   
Sales per share (Unadj.) Rs260.2491.2 53.0%  
Earnings per share (Unadj.) Rs19.0-3.2 -596.3%  
Cash flow per share (Unadj.) Rs33.114.4 229.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0376.5 56.6%  
Shares outstanding (eoy) m126.2020.54 614.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.10.6 364.1%   
Avg P/E ratio x28.9-89.3 -32.3%  
P/CF ratio (eoy) x16.619.7 84.1%  
Price / Book Value ratio x2.60.8 340.8%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1205,833 1,184.9%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,3592,179 337.7%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,83610,089 325.5%  
Other income Rs m418257 162.9%   
Total revenues Rs m33,25410,346 321.4%   
Gross profit Rs m4,505-792 -568.9%  
Depreciation Rs m1,777361 491.9%   
Interest Rs m2402,756 8.7%   
Profit before tax Rs m2,905-3,653 -79.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m511125 408.4%   
Profit after tax Rs m2,394-65 -3,663.7%  
Gross profit margin %13.7-7.8 -174.8%  
Effective tax rate %17.6-3.4 -513.5%   
Net profit margin %7.3-0.6 -1,125.7%  
BALANCE SHEET DATA
Current assets Rs m19,4559,240 210.6%   
Current liabilities Rs m10,0769,998 100.8%   
Net working cap to sales %28.6-7.5 -380.3%  
Current ratio x1.90.9 208.9%  
Inventory Days Days9846 211.4%  
Debtors Days Days6760 111.7%  
Net fixed assets Rs m20,26010,124 200.1%   
Share capital Rs m252206 122.7%   
"Free" reserves Rs m26,6335,582 477.1%   
Net worth Rs m26,8867,734 347.7%   
Long term debt Rs m2,3404,889 47.9%   
Total assets Rs m41,17322,882 179.9%  
Interest coverage x13.1-0.3 -4,025.7%   
Debt to equity ratio x0.10.6 13.8%  
Sales to assets ratio x0.80.4 180.9%   
Return on assets %6.411.8 54.4%  
Return on equity %8.9-0.8 -1,053.8%  
Return on capital %10.822.3 48.2%  
Exports to sales %47.63.0 1,567.6%   
Imports to sales %14.90.4 3,481.5%   
Exports (fob) Rs m15,642307 5,101.8%   
Imports (cif) Rs m4,88443 11,330.9%   
Fx inflow Rs m15,642307 5,101.8%   
Fx outflow Rs m4,884125 3,897.5%   
Net fx Rs m10,759181 5,934.1%   
CASH FLOW
From Operations Rs m3,41111,754 29.0%  
From Investments Rs m-1,354-561 241.6%  
From Financial Activity Rs m-1,304-6,762 19.3%  
Net Cashflow Rs m7534,432 17.0%  

Share Holding

Indian Promoters % 45.9 39.6 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.5 152.0%  
FIIs % 25.3 16.8 150.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 36.1 48.2%  
Shareholders   36,892 16,479 223.9%  
Pledged promoter(s) holding % 2.1 77.6 2.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades above 39,000-Mark; IndusInd Bank & ICICI Bank Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Barring telecom sector and FMCG sector, all sectoral indices are trading in green with stocks in the banking sector.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 18, 2019 02:25 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - GSK PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS